董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Ali Behbahani | 男 | Director | 49 | 11.78万美元 | 未持股 | 2025-03-31 |
| Christine Siu | 女 | Director | 48 | 12.40万美元 | 未持股 | 2025-03-31 |
| Jan Skvarka | 男 | Director | 58 | 11.14万美元 | 未持股 | 2025-03-31 |
| Kimberly Blackwell | 女 | Director | 56 | 12.34万美元 | 未持股 | 2025-03-31 |
| Chandra P. Leo | 男 | Director | 55 | 未披露 | 未持股 | 2025-03-31 |
| Markus Warmuth | 男 | Chief Executive Officer, President and Director | 54 | 244.08万美元 | 未持股 | 2025-03-31 |
| Jan Skvarka | 男 | Director | 58 | 未披露 | 未持股 | 2025-03-31 |
| Anthony Manning | 男 | Director | 63 | 11.25万美元 | 未持股 | 2025-03-31 |
| Eric Hughes | 男 | Director | 55 | 28.14万美元 | 未持股 | 2025-03-31 |
| Andrew Schiff | 男 | Director and Non-Executive Chair of the Board | 59 | 16.48万美元 | 未持股 | 2025-03-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Markus Warmuth | 男 | Chief Executive Officer, President and Director | 54 | 244.08万美元 | 未持股 | 2025-03-31 |
| Sharon Townson | 女 | Chief Scientific Officer | 50 | 未披露 | 未持股 | 2025-03-31 |
| Filip Janku | 男 | Chief Medical Officer | 51 | 125.79万美元 | 未持股 | 2025-03-31 |
| Philip Nickson | 男 | Chief Business and Legal Officer | 45 | 128.76万美元 | 未持股 | 2025-03-31 |
| Jennifer Champoux | 女 | Chief Operating Officer | 53 | 未披露 | 未持股 | 2025-03-31 |
| Andrew Schiff | 男 | Director and Non-Executive Chair of the Board | 59 | 16.48万美元 | 未持股 | 2025-03-31 |
董事简历
中英对照 | 中文 | 英文- Ali Behbahani
-
Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University. - Ali Behbahani，自2020年4月起担任Monte Rosa治疗公司董事会成员。Behbahani博士于2007年加入风险投资公司New Enterprise Associates，Inc.，是医疗保健部门的合伙人和联席主管。在加入New Enterprise Associates，Inc.之前，Behbahani博士曾于1998年至2000年在制药公司The Medicines Company担任业务发展顾问，在跨国投资银行和金融服务公司摩根士丹利担任风险投资助理，在全球金融服务公司雷曼兄弟担任医疗保健投资银行分析师。Behbahani博士担任生物技术公司Nkarta, Inc.的董事会成员，自2015年8月起，生物制药公司Black Diamond Therapeutics, Inc.，生物制药公司，自2018年12月起，生物制药公司Adaptimmune治疗 PLC，自2014年9月起，生物技术公司CRISPR Therapeutics AG，自2015年3月起，生物技术公司Korro Bio，Inc.，自2019年8月起，生物技术公司Arcellx, Inc.，自2015年2月起。Behbahani博士曾于2013年7月至2024年9月担任医疗器械公司CVRx, Inc.的董事会成员，全球医疗器械公司Nevro Corp.，2014年8月至2019年3月，生物制药公司Oyster Point Pharma, Inc.，2017年7月至2023年1月，生物制药公司Genocea Biosciences, Inc.，2018年2月至2022年5月，生物技术公司Minerva Surgical，2011年5月至2024年1月，以及生物技术公司TERM4，Inc.至2017年。Behbahani博士获得了宾夕法尼亚大学医学院的医学博士学位、宾夕法尼亚大学沃顿商学院的工商管理硕士学位以及杜克大学的生物医学工程、电气工程和化学学士学位。
- Ali Behbahani,has been a member of Monte Rosa Therapeutics, Inc. board of directors since April 2020. Dr. Behbahani joined New Enterprise Associates, Inc., a venture capital firm, in 2007 and is a Partner and Co-Head of Healthcare. Prior to joining New Enterprise Associates, Inc., Dr. Behbahani served as a consultant in business development at The Medicines Company, a pharmaceutical company, a Venture Associate at Morgan Stanley, a multinational investment bank and financial services company, and a Healthcare Investment Banking Analyst at Lehman Brothers, a global financial services firm, from 1998 to 2000. Dr. Behbahani serves as a member of the board of directors of Nkarta, Inc., a biotechnology company, since August 2015, Black Diamond Therapeutics, Inc., a biopharmaceutical company, since December 2018, Adaptimmune Therapeutics plc, a biopharmaceutical company, since September 2014, CRISPR Therapeutics AG, a biotechnology company, since March 2015, Korro Bio, Inc., a biotechnology company, since August 2019, and Arcellx, Inc., a biotechnology company, since February 2015. Dr. Behbahani formerly served as a member of the board of directors of CVRx, Inc., a medical device company, from July 2013 to September 2024, Nevro Corp., a global medical device company, from August 2014 to March 2019, Oyster Point Pharma, Inc., a biopharmaceutical company, from July 2017 to January 2023, Genocea Biosciences, Inc., a biopharmaceutical company, from February 2018 to May 2022, Minerva Surgical Inc., a biotechnology company, from May 2011 to January 2024, and Marker Therapeutics, Inc. until 2017. Dr. Behbahani received an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University.
- Christine Siu
-
Christine Siu自2017年12月起担任我们的首席财务官。2016年至2017年，她担任Eidos的首席运营官。她还担任Bridgebio其他子公司的首席运营官。在此之前，萧女士于2014年至2017年担任治疗额颞痴呆症的Bluefield项目的首席商务官。在此之前，她曾于2012年至2014年担任全球血液疗法公司企业发展高级总监。她曾担任Third Rock Ventures公司的风险负责人（2011年至2012年）。此前，她曾担任Warburg Pincus and Thomas，McNerney&Partners公司（私人股本和风险投资公司）的职务，在那里她曾投资生命科学公司。她在密歇根大学（University of Michigan）获得细胞分子生物学和经济学学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Christine Siu,has been a member of Monte Rosa Therapeutics, Inc. board of directors since December 2020. Ms. Siu has served as the Chief Executive Officer of ML Bio Solutions, an affiliate of BridgeBio Pharma Inc., a pharmaceutical company, since January 2022 and as Chief Executive Officer of Pancreative Sciences, a portfolio company of GondolaBio, LLC, a biopharma startup, since February 2025. She formerly served as the Chief Operating Officer in Residence of BridgeBio Pharma Inc., a pharmaceutical company, from January 2020 to January 2022 and as the Chief Financial Officer of Eidos Therapeutics, Inc., a biopharmaceutical company from December 2017 to December 2019 and previously as Chief Operating Officer of Eidos Therapeutics, Inc. from April 2016 to December 2017. Ms. Siu served as the Chief Business Officer of The Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017, and previously from 2012 to 2014 as Senior Director of Corporate Development at Global Blood Therapeutics, Inc., a biopharmaceutical company. Previously, she held positions at various private equity and venture capital firms, including Third Rock Ventures, LLC, Warburg Pincus LLC and Thomas, McNerney & Partners, LLC, where she invested in life sciences companies. Ms. Siu has served as a member of the board of directors of Bright Peak Therapeutics, Inc., a privately held biotechnology company, since June 2021. Ms. Siu received an M.B.A. from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan. - Christine Siu自2017年12月起担任我们的首席财务官。2016年至2017年，她担任Eidos的首席运营官。她还担任Bridgebio其他子公司的首席运营官。在此之前，萧女士于2014年至2017年担任治疗额颞痴呆症的Bluefield项目的首席商务官。在此之前，她曾于2012年至2014年担任全球血液疗法公司企业发展高级总监。她曾担任Third Rock Ventures公司的风险负责人（2011年至2012年）。此前，她曾担任Warburg Pincus and Thomas，McNerney&Partners公司（私人股本和风险投资公司）的职务，在那里她曾投资生命科学公司。她在密歇根大学（University of Michigan）获得细胞分子生物学和经济学学士学位，在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
- Christine Siu,has been a member of Monte Rosa Therapeutics, Inc. board of directors since December 2020. Ms. Siu has served as the Chief Executive Officer of ML Bio Solutions, an affiliate of BridgeBio Pharma Inc., a pharmaceutical company, since January 2022 and as Chief Executive Officer of Pancreative Sciences, a portfolio company of GondolaBio, LLC, a biopharma startup, since February 2025. She formerly served as the Chief Operating Officer in Residence of BridgeBio Pharma Inc., a pharmaceutical company, from January 2020 to January 2022 and as the Chief Financial Officer of Eidos Therapeutics, Inc., a biopharmaceutical company from December 2017 to December 2019 and previously as Chief Operating Officer of Eidos Therapeutics, Inc. from April 2016 to December 2017. Ms. Siu served as the Chief Business Officer of The Bluefield Project to Cure Frontotemporal Dementia from 2014 to 2017, and previously from 2012 to 2014 as Senior Director of Corporate Development at Global Blood Therapeutics, Inc., a biopharmaceutical company. Previously, she held positions at various private equity and venture capital firms, including Third Rock Ventures, LLC, Warburg Pincus LLC and Thomas, McNerney & Partners, LLC, where she invested in life sciences companies. Ms. Siu has served as a member of the board of directors of Bright Peak Therapeutics, Inc., a privately held biotechnology company, since June 2021. Ms. Siu received an M.B.A. from Harvard Business School and a B.S. with distinction in cellular molecular biology and economics from the University of Michigan.
- Jan Skvarka
-
Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
Jan Skvarka,has been a member of Monte Rosa Therapeutics, Inc. board of directors since March 2023. Dr. Skvarka serves as the Executive Chairman of DEM BioPharma, Inc, a privately held immune-oncology company, since March 2022 and as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since September 2022. He previously served as the Executive Chairman of GentiBio, Inc., a privately held biotherapeutics company, from June 2022 to November 2022. From September 2019 to November 2021, Dr. Skvarka was the President and Chief Executive Officer and a member of the board of directors of Trillium Therapeutics, Inc., a publicly traded, clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. From 2014 to January 2019, Dr. Skvarka served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company's strategy, built an accomplished leadership team, and oversaw its clinical development program. He also held roles of increasing responsibility at Bain & Company, most recently as a Partner, and was a leading member of Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka received a BS in business administration and a PhD in economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School. - Jan Skvarka自2019年9月25日起担任Trillium的总裁兼首席执行官。在加入Trillium之前，Skvarka博士于2014年至2018年担任马萨诸塞州波士顿临床阶段神经科学公司TAL Medical的总裁兼首席执行官。在TAL之前，Skvarka博士在波士顿贝恩公司（Bain&Company）担任了14年的梦百合顾问。从2007年到2013年，他是梦百合实践的合伙人，专注于制药、生物技术和医疗技术公司。职业生涯早期，Skvarka博士在Price Waterhouse位于伦敦、EK和奥地利维也纳的企业融资部门任职。
- Jan Skvarka,has been a member of Monte Rosa Therapeutics, Inc. board of directors since March 2023. Dr. Skvarka serves as the Executive Chairman of DEM BioPharma, Inc, a privately held immune-oncology company, since March 2022 and as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since September 2022. He previously served as the Executive Chairman of GentiBio, Inc., a privately held biotherapeutics company, from June 2022 to November 2022. From September 2019 to November 2021, Dr. Skvarka was the President and Chief Executive Officer and a member of the board of directors of Trillium Therapeutics, Inc., a publicly traded, clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. From 2014 to January 2019, Dr. Skvarka served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company's strategy, built an accomplished leadership team, and oversaw its clinical development program. He also held roles of increasing responsibility at Bain & Company, most recently as a Partner, and was a leading member of Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka received a BS in business administration and a PhD in economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School.
- Kimberly Blackwell
-
自2021年5月以来，Kimberly Blackwell一直担任我们的董事会成员。Blackwell博士自2020年3月起担任生物技术公司Tempus Labs，Inc.的首席医疗官兼临床肿瘤开发高级副总裁。在此之前，Blackwell博士于2018年3月至2020年3月担任制药公司礼来公司的早期免疫肿瘤学副总裁。在加入礼来之前，Blackwell博士于2012年7月至2018年3月在杜克医学中心和杜克癌症研究所担任医学系教授。Blackwell博士分别自2020年6月和7月起担任生物技术公司Monte Rosa Therapeutics，Inc.和上市临床阶段生物制药公司ZentalisPharmaceuticals，Inc.的董事会成员。自2017年2月以来，她还一直担任杜克天使网络的指导委员会成员，自2021年1月以来，她一直担任Artemis Women’；S Health Fund的科学顾问委员会成员。布莱克韦尔博士获得了杜克大学的生物伦理学学士学位和梅奥诊所医学院的医学博士学位。
Kimberly Blackwell,has been a member of Monte Rosa Therapeutics, Inc. board of directors since July 2020. Dr. Blackwell served as Chief Executive Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from May 2022 to November 2024. Dr. Blackwell formerly served as Chief Medical Officer of Tempus Labs, Inc., a biotechnology company, from March 2020 to May 2022 and as Vice President of Early Phase Oncology and Immuno-oncology at Eli Lilly and Company, a global pharmaceutical company, from March 2018 to March 2020. From 2012 to 2018, Dr. Blackwell served as Director of the Women's Cancer Program, Professor of Medicine, and Associate Director for Strategic Relations at the Duke Cancer Institute where she led the clinical development teams for promising early stage therapeutics. Dr. Blackwell serves as a member of the board of directors of Century Therapeutics, a biotechnology company, since June 2021. Dr. Blackwell formerly served as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from July 2020 to November 2024. Dr. Blackwell received an M.D. from the Mayo Clinic College of Medicine and Science and a B.A. in bioethics from Duke University. - 自2021年5月以来，Kimberly Blackwell一直担任我们的董事会成员。Blackwell博士自2020年3月起担任生物技术公司Tempus Labs，Inc.的首席医疗官兼临床肿瘤开发高级副总裁。在此之前，Blackwell博士于2018年3月至2020年3月担任制药公司礼来公司的早期免疫肿瘤学副总裁。在加入礼来之前，Blackwell博士于2012年7月至2018年3月在杜克医学中心和杜克癌症研究所担任医学系教授。Blackwell博士分别自2020年6月和7月起担任生物技术公司Monte Rosa Therapeutics，Inc.和上市临床阶段生物制药公司ZentalisPharmaceuticals，Inc.的董事会成员。自2017年2月以来，她还一直担任杜克天使网络的指导委员会成员，自2021年1月以来，她一直担任Artemis Women’；S Health Fund的科学顾问委员会成员。布莱克韦尔博士获得了杜克大学的生物伦理学学士学位和梅奥诊所医学院的医学博士学位。
- Kimberly Blackwell,has been a member of Monte Rosa Therapeutics, Inc. board of directors since July 2020. Dr. Blackwell served as Chief Executive Officer at Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from May 2022 to November 2024. Dr. Blackwell formerly served as Chief Medical Officer of Tempus Labs, Inc., a biotechnology company, from March 2020 to May 2022 and as Vice President of Early Phase Oncology and Immuno-oncology at Eli Lilly and Company, a global pharmaceutical company, from March 2018 to March 2020. From 2012 to 2018, Dr. Blackwell served as Director of the Women's Cancer Program, Professor of Medicine, and Associate Director for Strategic Relations at the Duke Cancer Institute where she led the clinical development teams for promising early stage therapeutics. Dr. Blackwell serves as a member of the board of directors of Century Therapeutics, a biotechnology company, since June 2021. Dr. Blackwell formerly served as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, from July 2020 to November 2024. Dr. Blackwell received an M.D. from the Mayo Clinic College of Medicine and Science and a B.A. in bioethics from Duke University.
- Chandra P. Leo
-
Chandra P.利欧股份自2020年9月以来一直是我们的董事会成员。利欧股份博士自2007年以来一直担任HBM Partners AG（一家瑞士医疗保健投资公司）私募股权团队的投资顾问。在加入HBM Partners AG之前，利欧股份博士曾在斯坦福大学担任博士后科学家，在莱比锡大学医院担任医师，并在风险投资公司Wellington Partners担任负责人。利欧股份博士目前担任Fore Biotherapeutics Inc.，River2Renal Corp.和River3Renal Corp.（均为生物技术公司）和GyneSonics Inc.（医疗设备公司）的董事会董事。他在柏林自由大学获得医学博士学位，在欧洲工商管理学院获得工商管理硕士学位，在巴塞尔大学获得医药开发硕士学位。
Chandra P. Leo,has been a member of Monte Rosa Therapeutics, Inc. board of directors since September 2020. Dr. Leo has served as an Investment Advisor in the private equity team at HBM Partners AG, a Swiss healthcare investment company, since 2007. Between 1997 and 2007, Dr. Leo worked as a postdoctoral scientist at Stanford University, as a physician at the University Hospital Leipzig and as a principal at Wellington Partners, a venture capital firm. Dr. Leo currently serves as a director on the boards of Fore Biotherapeutics Inc., River 2 Renal Corp. and River 3 Renal Corp., all of which are biotechnology companies. Dr. Leo previously served as a member of the board of directors of Gynesonics Inc., a privately held medical device company, Galecto, Inc., a biotechnology company, and Longboard Pharmaceuticals, Inc., a biopharmaceutical company. He received an M.D. from the Freie Universitt Berlin, an M.B.A from INSEAD and an M.A.S. in medicines development from the University of Bsel. - Chandra P.利欧股份自2020年9月以来一直是我们的董事会成员。利欧股份博士自2007年以来一直担任HBM Partners AG（一家瑞士医疗保健投资公司）私募股权团队的投资顾问。在加入HBM Partners AG之前，利欧股份博士曾在斯坦福大学担任博士后科学家，在莱比锡大学医院担任医师，并在风险投资公司Wellington Partners担任负责人。利欧股份博士目前担任Fore Biotherapeutics Inc.，River2Renal Corp.和River3Renal Corp.（均为生物技术公司）和GyneSonics Inc.（医疗设备公司）的董事会董事。他在柏林自由大学获得医学博士学位，在欧洲工商管理学院获得工商管理硕士学位，在巴塞尔大学获得医药开发硕士学位。
- Chandra P. Leo,has been a member of Monte Rosa Therapeutics, Inc. board of directors since September 2020. Dr. Leo has served as an Investment Advisor in the private equity team at HBM Partners AG, a Swiss healthcare investment company, since 2007. Between 1997 and 2007, Dr. Leo worked as a postdoctoral scientist at Stanford University, as a physician at the University Hospital Leipzig and as a principal at Wellington Partners, a venture capital firm. Dr. Leo currently serves as a director on the boards of Fore Biotherapeutics Inc., River 2 Renal Corp. and River 3 Renal Corp., all of which are biotechnology companies. Dr. Leo previously served as a member of the board of directors of Gynesonics Inc., a privately held medical device company, Galecto, Inc., a biotechnology company, and Longboard Pharmaceuticals, Inc., a biopharmaceutical company. He received an M.D. from the Freie Universitt Berlin, an M.B.A from INSEAD and an M.A.S. in medicines development from the University of Bsel.
- Markus Warmuth
-
Markus Warmuth，他一直担任Monte Rosa Therapeutics, Inc.的总裁、首席执行官和董事会成员（2020年1月以来）。他还担任Versant Venture Management, LLC（医疗投资公司）的风险合伙人（2019年9月以来）。从2018年7月到2019年8月，他担任Third Rock Ventures, LLC（风险投资公司）的常驻企业家。2011年10月至2018年5月，他担任H3 Biomedicine Inc.（一家药物开发公司）的首席执行官，此前从2011年8月至2011年10月担任首席科学官。他曾担任IMV Inc.（临床阶段生物制药公司）的董事会成员（2018年11月以来），此前曾担任Relay Therapeutics, Inc.（药物发现公司）的董事会成员（2018年9月至2019年8月）。他获得了德国慕尼黑路德维希马克西米兰大学的医学博士学位。
Markus Warmuth,has served as Monte Rosa Therapeutics, Inc. President and Chief Executive Officer and a member of Monte Rosa Therapeutics, Inc. board of directors since January 2020. Dr. Warmuth has also served as a Venture Partner at Versant Venture Management, LLC, a healthcare investment firm, from September 2019 to January 2024. From July 2018 to August 2019, he worked as an Entrepreneur-in-Residence for Third Rock Ventures, LLC, a venture capital firm. From October 2011 to May 2018, Dr. Warmuth was the Chief Executive Officer and, previously from August 2011 to October 2011, Chief Scientific Officer of H3 Biomedicine Inc., a drug development company. Dr. Warmuth has served as a member of the board of directors of IMV Inc., a clinical stage biopharmaceutical company, from November 2018 to September 2023, and Relay Therapeutics, a clinical stage precision medicine company, from July 2018 to August 2019. Dr. Warmuth has also previously served in multiple roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology, Head of Oncology Pharmacology. While at Novartis, he and his teams were involved in the development of Ceritinib and Ribociclib as well as the discovery of allosteric inhibitors of SHP2 and Abl, amongst others. He received an M.D. from Ludwig Maximilian University, Munich, Germany. - Markus Warmuth，他一直担任Monte Rosa Therapeutics, Inc.的总裁、首席执行官和董事会成员（2020年1月以来）。他还担任Versant Venture Management, LLC（医疗投资公司）的风险合伙人（2019年9月以来）。从2018年7月到2019年8月，他担任Third Rock Ventures, LLC（风险投资公司）的常驻企业家。2011年10月至2018年5月，他担任H3 Biomedicine Inc.（一家药物开发公司）的首席执行官，此前从2011年8月至2011年10月担任首席科学官。他曾担任IMV Inc.（临床阶段生物制药公司）的董事会成员（2018年11月以来），此前曾担任Relay Therapeutics, Inc.（药物发现公司）的董事会成员（2018年9月至2019年8月）。他获得了德国慕尼黑路德维希马克西米兰大学的医学博士学位。
- Markus Warmuth,has served as Monte Rosa Therapeutics, Inc. President and Chief Executive Officer and a member of Monte Rosa Therapeutics, Inc. board of directors since January 2020. Dr. Warmuth has also served as a Venture Partner at Versant Venture Management, LLC, a healthcare investment firm, from September 2019 to January 2024. From July 2018 to August 2019, he worked as an Entrepreneur-in-Residence for Third Rock Ventures, LLC, a venture capital firm. From October 2011 to May 2018, Dr. Warmuth was the Chief Executive Officer and, previously from August 2011 to October 2011, Chief Scientific Officer of H3 Biomedicine Inc., a drug development company. Dr. Warmuth has served as a member of the board of directors of IMV Inc., a clinical stage biopharmaceutical company, from November 2018 to September 2023, and Relay Therapeutics, a clinical stage precision medicine company, from July 2018 to August 2019. Dr. Warmuth has also previously served in multiple roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology, Head of Oncology Pharmacology. While at Novartis, he and his teams were involved in the development of Ceritinib and Ribociclib as well as the discovery of allosteric inhibitors of SHP2 and Abl, amongst others. He received an M.D. from Ludwig Maximilian University, Munich, Germany.
- Jan Skvarka
-
Jan Skvarka，自2023年3月起担任Monte Rosa Therapeutics，Inc.董事会成员。Skvarka博士自2022年3月起担任私营免疫肿瘤学公司DEM BioPharma，Inc的执行主席，并自2022年9月起担任临床阶段生物制药公司Zentalis Pharmaceuticals, Inc.的董事会成员。他此前曾于2022年6月至2022年11月担任私人控股的生物治疗公司GentiBio，Inc.的执行董事长。从2019年9月到2021年11月，Skvarka博士担任延龄草治疗公司的总裁兼首席执行官和董事会成员，该公司是一家上市的临床阶段免疫肿瘤学公司，在那里他领导了一场非常成功的360度业务转型，该转型产生了一种领先的CD47候选药物，推动Trillium在两年内从1600万美元的市值发展到被辉瑞公司以23亿美元的价格收购。从2014年到2019年1月，Skvarka博士担任Tal Medical的总裁兼首席执行官，Tal Medical是一家私营临床阶段的神经调节公司，在那里他制定并执行了公司的战略，建立了一支成就卓著的领导团队，并监督其临床开发计划。他还在贝恩公司担任越来越多的职责，最近担任合伙人，并且是贝恩医疗实践的主要成员，专注于生命科学。Skvarka博士在斯洛伐克布拉迪斯拉发经济大学获得工商管理学士学位和经济学博士学位，并在哈佛商学院获得MBA学位。
Jan Skvarka,has been a member of Monte Rosa Therapeutics, Inc. board of directors since March 2023. Dr. Skvarka serves as the Executive Chairman of DEM BioPharma, Inc, a privately held immune-oncology company, since March 2022 and as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since September 2022. He previously served as the Executive Chairman of GentiBio, Inc., a privately held biotherapeutics company, from June 2022 to November 2022. From September 2019 to November 2021, Dr. Skvarka was the President and Chief Executive Officer and a member of the board of directors of Trillium Therapeutics, Inc., a publicly traded, clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. From 2014 to January 2019, Dr. Skvarka served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company's strategy, built an accomplished leadership team, and oversaw its clinical development program. He also held roles of increasing responsibility at Bain & Company, most recently as a Partner, and was a leading member of Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka received a BS in business administration and a PhD in economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School. - Jan Skvarka，自2023年3月起担任Monte Rosa Therapeutics，Inc.董事会成员。Skvarka博士自2022年3月起担任私营免疫肿瘤学公司DEM BioPharma，Inc的执行主席，并自2022年9月起担任临床阶段生物制药公司Zentalis Pharmaceuticals, Inc.的董事会成员。他此前曾于2022年6月至2022年11月担任私人控股的生物治疗公司GentiBio，Inc.的执行董事长。从2019年9月到2021年11月，Skvarka博士担任延龄草治疗公司的总裁兼首席执行官和董事会成员，该公司是一家上市的临床阶段免疫肿瘤学公司，在那里他领导了一场非常成功的360度业务转型，该转型产生了一种领先的CD47候选药物，推动Trillium在两年内从1600万美元的市值发展到被辉瑞公司以23亿美元的价格收购。从2014年到2019年1月，Skvarka博士担任Tal Medical的总裁兼首席执行官，Tal Medical是一家私营临床阶段的神经调节公司，在那里他制定并执行了公司的战略，建立了一支成就卓著的领导团队，并监督其临床开发计划。他还在贝恩公司担任越来越多的职责，最近担任合伙人，并且是贝恩医疗实践的主要成员，专注于生命科学。Skvarka博士在斯洛伐克布拉迪斯拉发经济大学获得工商管理学士学位和经济学博士学位，并在哈佛商学院获得MBA学位。
- Jan Skvarka,has been a member of Monte Rosa Therapeutics, Inc. board of directors since March 2023. Dr. Skvarka serves as the Executive Chairman of DEM BioPharma, Inc, a privately held immune-oncology company, since March 2022 and as a member of the board of directors of Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, since September 2022. He previously served as the Executive Chairman of GentiBio, Inc., a privately held biotherapeutics company, from June 2022 to November 2022. From September 2019 to November 2021, Dr. Skvarka was the President and Chief Executive Officer and a member of the board of directors of Trillium Therapeutics, Inc., a publicly traded, clinical-stage immuno-oncology company, where he led a highly successful, 360-degree business transformation that produced a leading CD47 drug candidate, propelling Trillium from a $16 million market capitalization to a $2.3 billion acquisition by Pfizer Inc. in two years. From 2014 to January 2019, Dr. Skvarka served as the President and Chief Executive Officer of Tal Medical, a private clinical-stage neuromodulation company, where he developed and executed the company's strategy, built an accomplished leadership team, and oversaw its clinical development program. He also held roles of increasing responsibility at Bain & Company, most recently as a Partner, and was a leading member of Bain Healthcare Practice, with a focus on life sciences. Dr. Skvarka received a BS in business administration and a PhD in economics from the University of Economics in Bratislava, Slovakia, and an MBA from Harvard Business School.
- Anthony Manning
-
Anthony Manning，自2023年7月起担任Monte Rosa治疗公司董事会成员。Manning是一位经验丰富的生物化学家，在制药和生物技术行业拥有30年的职业生涯，目前是Manning Bio Worldwide，LLC的负责人，协助开发变革性药物。他还担任生物制药公司PALATIN技术的董事会董事，自2017年9月起担任生物医学创业研究院主席，自2021年起担任多个组织的科学顾问，并自2024年8月起担任私营生物技术公司Cyrus Biotechnology的董事会董事。作为生物制药公司摩蒙塔制药的前任首席科学官，从2018年到2021年3月，他在那里建立了一流疗法的管道，导致该公司在2020年被强生以65亿美元的价格收购。更早之前，他曾于2007年至2011年在生物制药公司渤健 Idec、2002年至2007年在罗氏制药公司（Roche Pharmaceuticals）（研究医疗保健公司Roche Holding AG的制药部门）以及2000年至2002年在Pharmacia Corp（一家于2003年与辉瑞合并的制药公司）领导研究和药物发现工作。
Anthony Manning,has been a member of Monte Rosa Therapeutics, Inc. board of directors since July 2023. Manning is a seasoned biochemist with a 30-year career in the pharmaceutical and biotechnology industry and currently is the Principal at Manning Bio Worldwide, LLC, assisting in the development of transformative medicines. He also serves as a Board Director for Palatin Technologies, a biopharmaceutical company, since September 2017, as Chairman of the Institute for Biomedical Entrepreneurship, and as a Scientific Advisor for several organizations since 2021, and a Board Director for Cyrus Biotechnology, a privately-held biotechnology company since August 2024. As the former Chief Scientific Officer at Momenta Pharmaceuticals, a biopharmaceutical company, from 2018 to March 2021, where he built a pipeline of first-in-class therapeutics, leading to the company's acquisition by Johnson & Johnson for $6.5 billion in 2020. Earlier, he spearheaded research and drug discovery at Biogen Idec, a biopharmaceutical company, from 2007 to 2011, at Roche Pharmaceuticals, the pharmaceutical division of research healthcare company Roche Holding AG, from 2002 to 2007, and at Pharmacia Corp, a pharmaceutical company that merged with Pfizer in 2003, from 2000 to 2002. - Anthony Manning，自2023年7月起担任Monte Rosa治疗公司董事会成员。Manning是一位经验丰富的生物化学家，在制药和生物技术行业拥有30年的职业生涯，目前是Manning Bio Worldwide，LLC的负责人，协助开发变革性药物。他还担任生物制药公司PALATIN技术的董事会董事，自2017年9月起担任生物医学创业研究院主席，自2021年起担任多个组织的科学顾问，并自2024年8月起担任私营生物技术公司Cyrus Biotechnology的董事会董事。作为生物制药公司摩蒙塔制药的前任首席科学官，从2018年到2021年3月，他在那里建立了一流疗法的管道，导致该公司在2020年被强生以65亿美元的价格收购。更早之前，他曾于2007年至2011年在生物制药公司渤健 Idec、2002年至2007年在罗氏制药公司（Roche Pharmaceuticals）（研究医疗保健公司Roche Holding AG的制药部门）以及2000年至2002年在Pharmacia Corp（一家于2003年与辉瑞合并的制药公司）领导研究和药物发现工作。
- Anthony Manning,has been a member of Monte Rosa Therapeutics, Inc. board of directors since July 2023. Manning is a seasoned biochemist with a 30-year career in the pharmaceutical and biotechnology industry and currently is the Principal at Manning Bio Worldwide, LLC, assisting in the development of transformative medicines. He also serves as a Board Director for Palatin Technologies, a biopharmaceutical company, since September 2017, as Chairman of the Institute for Biomedical Entrepreneurship, and as a Scientific Advisor for several organizations since 2021, and a Board Director for Cyrus Biotechnology, a privately-held biotechnology company since August 2024. As the former Chief Scientific Officer at Momenta Pharmaceuticals, a biopharmaceutical company, from 2018 to March 2021, where he built a pipeline of first-in-class therapeutics, leading to the company's acquisition by Johnson & Johnson for $6.5 billion in 2020. Earlier, he spearheaded research and drug discovery at Biogen Idec, a biopharmaceutical company, from 2007 to 2011, at Roche Pharmaceuticals, the pharmaceutical division of research healthcare company Roche Holding AG, from 2002 to 2007, and at Pharmacia Corp, a pharmaceutical company that merged with Pfizer in 2003, from 2000 to 2002.
- Eric Hughes
-
Eric Hughes，自2024年12月起担任Monte Rosa治疗公司董事会成员。休斯博士担任梯瓦制药工业有限公司执行副总裁、全球研发和首席医疗官，自2022年8月起担任该职务。在加入梯瓦制药之前，2021年至2022年，Hughes博士担任福泰制药临床开发和转化医学高级副总裁。从2015年到2021年，休斯博士担任诺华免疫学、肝病学和皮肤病学的全球开发部门负责人，最终负责领导多个治疗领域的所有临床开发活动和生物统计学家人才，并负责扩大在中国的发展。此外，在2020年至2021年期间，在新冠疫情大流行期间，休斯博士还担任了美国国立卫生研究院加速新冠治疗干预和疫苗公私伙伴关系治疗学临床工作组的联合主席。从2010年到2015年，休斯博士在百时美施贵宝担任过多个高管和高级职位，包括病毒学、纤维化疾病、遗传定义疾病、自身免疫、心脏病学发现医学、探索性临床和转化研究的负责人。休斯博士在耶鲁大学医学院获得医学博士和博士学位。
Eric Hughes,has been a member of Monte Rosa Therapeutics, Inc. board of directors since December 2024. Dr. Hughes serves as Executive Vice President, Global R&D and Chief Medical Officer at Teva Pharmaceuticals Industries Ltd., a role he has held since August 2022. Prior to joining Teva Pharmaceuticals, from 2021 to 2022, Dr. Hughes was Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. From 2015 to 2021, Dr. Hughes served as Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis, ultimately responsible for leading all clinical development activities and biostatistician talent across multiple therapeutic areas and for expanding development in China. Additionally, between 2020 and 2021, during the COVID-19 pandemic, Dr. Hughes also served as Co-Chair of the Therapeutics Clinical Working Group for the Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership at the National Institutes of Health. From 2010 to 2015, Dr. Hughes held several executive and senior positions at Bristol Myers-Squibb, including Head of Virology, Fibrotic Diseases, Genetically Defined Diseases, Autoimmunity, and Cardiology Discovery Medicine, Exploratory Clinical & Translational Research. Dr. Hughes received his MD and Ph.D. from Yale School of Medicine. - Eric Hughes，自2024年12月起担任Monte Rosa治疗公司董事会成员。休斯博士担任梯瓦制药工业有限公司执行副总裁、全球研发和首席医疗官，自2022年8月起担任该职务。在加入梯瓦制药之前，2021年至2022年，Hughes博士担任福泰制药临床开发和转化医学高级副总裁。从2015年到2021年，休斯博士担任诺华免疫学、肝病学和皮肤病学的全球开发部门负责人，最终负责领导多个治疗领域的所有临床开发活动和生物统计学家人才，并负责扩大在中国的发展。此外，在2020年至2021年期间，在新冠疫情大流行期间，休斯博士还担任了美国国立卫生研究院加速新冠治疗干预和疫苗公私伙伴关系治疗学临床工作组的联合主席。从2010年到2015年，休斯博士在百时美施贵宝担任过多个高管和高级职位，包括病毒学、纤维化疾病、遗传定义疾病、自身免疫、心脏病学发现医学、探索性临床和转化研究的负责人。休斯博士在耶鲁大学医学院获得医学博士和博士学位。
- Eric Hughes,has been a member of Monte Rosa Therapeutics, Inc. board of directors since December 2024. Dr. Hughes serves as Executive Vice President, Global R&D and Chief Medical Officer at Teva Pharmaceuticals Industries Ltd., a role he has held since August 2022. Prior to joining Teva Pharmaceuticals, from 2021 to 2022, Dr. Hughes was Senior Vice President of Clinical Development and Translational Medicine at Vertex Pharmaceuticals. From 2015 to 2021, Dr. Hughes served as Global Development Unit Head for Immunology, Hepatology and Dermatology at Novartis, ultimately responsible for leading all clinical development activities and biostatistician talent across multiple therapeutic areas and for expanding development in China. Additionally, between 2020 and 2021, during the COVID-19 pandemic, Dr. Hughes also served as Co-Chair of the Therapeutics Clinical Working Group for the Accelerating COVID-19 Therapeutic Interventions and Vaccines public-private partnership at the National Institutes of Health. From 2010 to 2015, Dr. Hughes held several executive and senior positions at Bristol Myers-Squibb, including Head of Virology, Fibrotic Diseases, Genetically Defined Diseases, Autoimmunity, and Cardiology Discovery Medicine, Exploratory Clinical & Translational Research. Dr. Hughes received his MD and Ph.D. from Yale School of Medicine.
- Andrew Schiff
-
Andrew Schiff，自2020年9月起担任Monte Rosa Therapeutics，Inc.董事会成员，自2023年6月起担任Monte Rosa Therapeutics，Inc.董事长。Schiff博士担任Aisling Capital的管理合伙人，Aisling Capital是一家风险投资公司，他自1999年以来一直隶属于该公司。在加入Aisling Capital之前，Schiff博士在纽约长老会医院从事内科工作，目前他在那里保持着医学临床助理教授的职位。Schiff博士自2017年起担任制药公司Aclaris Therapeutics, Inc.的董事会成员。Schiff博士获得了康奈尔大学医学院的医学博士学位、哥伦比亚大学商学院的工商管理硕士学位，以及布朗大学的神经科学荣誉学士学位。
Andrew Schiff,has been a member of Monte Rosa Therapeutics, Inc. board of directors since September 2020 and as Monte Rosa Therapeutics, Inc. chairman since June 2023. Dr. Schiff serves as a Managing Partner of Aisling Capital, a venture capital firm, that he has been affiliated with since 1999. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at the New York Presbyterian Hospital, where he currently maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff serves as a member of the board of directors of Aclaris Therapeutics, Inc., a pharmaceutical company, since 2017. Dr. Schiff received an M.D. from Cornell University Medical College, an M.B.A. from Columbia Business School, and a B.S. in neuroscience with honors from Brown University. - Andrew Schiff，自2020年9月起担任Monte Rosa Therapeutics，Inc.董事会成员，自2023年6月起担任Monte Rosa Therapeutics，Inc.董事长。Schiff博士担任Aisling Capital的管理合伙人，Aisling Capital是一家风险投资公司，他自1999年以来一直隶属于该公司。在加入Aisling Capital之前，Schiff博士在纽约长老会医院从事内科工作，目前他在那里保持着医学临床助理教授的职位。Schiff博士自2017年起担任制药公司Aclaris Therapeutics, Inc.的董事会成员。Schiff博士获得了康奈尔大学医学院的医学博士学位、哥伦比亚大学商学院的工商管理硕士学位，以及布朗大学的神经科学荣誉学士学位。
- Andrew Schiff,has been a member of Monte Rosa Therapeutics, Inc. board of directors since September 2020 and as Monte Rosa Therapeutics, Inc. chairman since June 2023. Dr. Schiff serves as a Managing Partner of Aisling Capital, a venture capital firm, that he has been affiliated with since 1999. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at the New York Presbyterian Hospital, where he currently maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff serves as a member of the board of directors of Aclaris Therapeutics, Inc., a pharmaceutical company, since 2017. Dr. Schiff received an M.D. from Cornell University Medical College, an M.B.A. from Columbia Business School, and a B.S. in neuroscience with honors from Brown University.
高管简历
中英对照 | 中文 | 英文- Markus Warmuth
Markus Warmuth，他一直担任Monte Rosa Therapeutics, Inc.的总裁、首席执行官和董事会成员（2020年1月以来）。他还担任Versant Venture Management, LLC（医疗投资公司）的风险合伙人（2019年9月以来）。从2018年7月到2019年8月，他担任Third Rock Ventures, LLC（风险投资公司）的常驻企业家。2011年10月至2018年5月，他担任H3 Biomedicine Inc.（一家药物开发公司）的首席执行官，此前从2011年8月至2011年10月担任首席科学官。他曾担任IMV Inc.（临床阶段生物制药公司）的董事会成员（2018年11月以来），此前曾担任Relay Therapeutics, Inc.（药物发现公司）的董事会成员（2018年9月至2019年8月）。他获得了德国慕尼黑路德维希马克西米兰大学的医学博士学位。
Markus Warmuth,has served as Monte Rosa Therapeutics, Inc. President and Chief Executive Officer and a member of Monte Rosa Therapeutics, Inc. board of directors since January 2020. Dr. Warmuth has also served as a Venture Partner at Versant Venture Management, LLC, a healthcare investment firm, from September 2019 to January 2024. From July 2018 to August 2019, he worked as an Entrepreneur-in-Residence for Third Rock Ventures, LLC, a venture capital firm. From October 2011 to May 2018, Dr. Warmuth was the Chief Executive Officer and, previously from August 2011 to October 2011, Chief Scientific Officer of H3 Biomedicine Inc., a drug development company. Dr. Warmuth has served as a member of the board of directors of IMV Inc., a clinical stage biopharmaceutical company, from November 2018 to September 2023, and Relay Therapeutics, a clinical stage precision medicine company, from July 2018 to August 2019. Dr. Warmuth has also previously served in multiple roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology, Head of Oncology Pharmacology. While at Novartis, he and his teams were involved in the development of Ceritinib and Ribociclib as well as the discovery of allosteric inhibitors of SHP2 and Abl, amongst others. He received an M.D. from Ludwig Maximilian University, Munich, Germany.- Markus Warmuth，他一直担任Monte Rosa Therapeutics, Inc.的总裁、首席执行官和董事会成员（2020年1月以来）。他还担任Versant Venture Management, LLC（医疗投资公司）的风险合伙人（2019年9月以来）。从2018年7月到2019年8月，他担任Third Rock Ventures, LLC（风险投资公司）的常驻企业家。2011年10月至2018年5月，他担任H3 Biomedicine Inc.（一家药物开发公司）的首席执行官，此前从2011年8月至2011年10月担任首席科学官。他曾担任IMV Inc.（临床阶段生物制药公司）的董事会成员（2018年11月以来），此前曾担任Relay Therapeutics, Inc.（药物发现公司）的董事会成员（2018年9月至2019年8月）。他获得了德国慕尼黑路德维希马克西米兰大学的医学博士学位。
- Markus Warmuth,has served as Monte Rosa Therapeutics, Inc. President and Chief Executive Officer and a member of Monte Rosa Therapeutics, Inc. board of directors since January 2020. Dr. Warmuth has also served as a Venture Partner at Versant Venture Management, LLC, a healthcare investment firm, from September 2019 to January 2024. From July 2018 to August 2019, he worked as an Entrepreneur-in-Residence for Third Rock Ventures, LLC, a venture capital firm. From October 2011 to May 2018, Dr. Warmuth was the Chief Executive Officer and, previously from August 2011 to October 2011, Chief Scientific Officer of H3 Biomedicine Inc., a drug development company. Dr. Warmuth has served as a member of the board of directors of IMV Inc., a clinical stage biopharmaceutical company, from November 2018 to September 2023, and Relay Therapeutics, a clinical stage precision medicine company, from July 2018 to August 2019. Dr. Warmuth has also previously served in multiple roles at the Novartis Institutes for Biomedical Research (NIBR) and the Genomics Institute of the Novartis Research Foundation (GNF), including as the Director of Kinase Biology, Head of Oncology Pharmacology. While at Novartis, he and his teams were involved in the development of Ceritinib and Ribociclib as well as the discovery of allosteric inhibitors of SHP2 and Abl, amongst others. He received an M.D. from Ludwig Maximilian University, Munich, Germany.
- Sharon Townson
Sharon Townson自2021年1月起担任我们的首席技术官，此前曾于2020年7月至2020年12月担任我们的生物分子科学副总裁。从2019年4月至2020年6月，Townson博士担任生物制药公司KymeraTherapeutics，Inc.的执行董事兼平台生物学主管。从2013年6月至2018年12月，Townson博士在生物技术公司Warp Drive Bio，Inc.担任过多个职务，包括物理生物化学科学总监，物理生物化学总监以及生物化学和生物物理学副总监。Townson博士拥有曼彻斯特大学科学技术学院的分子生物学和生物化学博士学位以及索尔福德大学的生物分子科学学士学位。
Sharon Townson,has served as Monte Rosa Therapeutics, Inc. Chief Scientific Officer since May 2024. From December 2020 to April 2024, Dr. Townson served as Monte Rosa Therapeutics, Inc. Chief Technology Officer. Dr. Townson originally joined Monte Rosa on July 2020 as Vice President, Biomolecular Sciences. Prior to joining Monte Rosa, Dr. Townson served as Executive Director of Platform Biology at Kymera Therapeutics from April 2019 to July 2020. Previously, from June 2013 to December 2018, Dr. Townson served in various leadership roles at Warp Drive Bio and was responsible for developing their novel molecular glue approach to target KRAS. Dr. Townson began her career at Pfizer as a structural biologist and holds a Ph.D. in structural biology and biochemistry from the University of Manchester Institute of Technology.- Sharon Townson自2021年1月起担任我们的首席技术官，此前曾于2020年7月至2020年12月担任我们的生物分子科学副总裁。从2019年4月至2020年6月，Townson博士担任生物制药公司KymeraTherapeutics，Inc.的执行董事兼平台生物学主管。从2013年6月至2018年12月，Townson博士在生物技术公司Warp Drive Bio，Inc.担任过多个职务，包括物理生物化学科学总监，物理生物化学总监以及生物化学和生物物理学副总监。Townson博士拥有曼彻斯特大学科学技术学院的分子生物学和生物化学博士学位以及索尔福德大学的生物分子科学学士学位。
- Sharon Townson,has served as Monte Rosa Therapeutics, Inc. Chief Scientific Officer since May 2024. From December 2020 to April 2024, Dr. Townson served as Monte Rosa Therapeutics, Inc. Chief Technology Officer. Dr. Townson originally joined Monte Rosa on July 2020 as Vice President, Biomolecular Sciences. Prior to joining Monte Rosa, Dr. Townson served as Executive Director of Platform Biology at Kymera Therapeutics from April 2019 to July 2020. Previously, from June 2013 to December 2018, Dr. Townson served in various leadership roles at Warp Drive Bio and was responsible for developing their novel molecular glue approach to target KRAS. Dr. Townson began her career at Pfizer as a structural biologist and holds a Ph.D. in structural biology and biochemistry from the University of Manchester Institute of Technology.
- Filip Janku
Filip Janku自2021年6月起担任我们的首席医疗官。从2012年2月到2021年5月，Janku博士在德克萨斯大学MD安德森癌症中心或MD安德森担任过各种职务，包括担任MD Anderson’；s临床和转化研究中心的中心医学总监，以及其研究癌症治疗学系的副教授，在那里他专注于致癌性突变和分子像差的研究工作。扬库博士获得了捷克共和国查尔斯大学的医学博士和博士学位。
Filip Janku,has served as Monte Rosa Therapeutics, Inc. Chief Medical Officer since June 2021. From February 2009 to May 2021, Dr. Janku served in various positions at The University of Texas MD Anderson Cancer Center, or MD Anderson, including as Center Medical Director for MD Anderson's Clinical and Translational Research Center and as Associate Professor in its Department of Investigational Cancer Therapeutics where he focused his research efforts in oncogenic mutations and molecular aberrations.Dr. Janku's work has been recognized with multiple awards including the Emil Frei, III Award for Excellence in Translational Research, Sabin Family Fellow Award, Khalifa Scholar Award, Sidney Kimmel Scholar Award; and he authored or coauthored over 290 scientific articles in peer-reviewed journals. Dr. Janku received his M.D. and Ph.D. from Charles University in the Czech Republic.- Filip Janku自2021年6月起担任我们的首席医疗官。从2012年2月到2021年5月，Janku博士在德克萨斯大学MD安德森癌症中心或MD安德森担任过各种职务，包括担任MD Anderson’；s临床和转化研究中心的中心医学总监，以及其研究癌症治疗学系的副教授，在那里他专注于致癌性突变和分子像差的研究工作。扬库博士获得了捷克共和国查尔斯大学的医学博士和博士学位。
- Filip Janku,has served as Monte Rosa Therapeutics, Inc. Chief Medical Officer since June 2021. From February 2009 to May 2021, Dr. Janku served in various positions at The University of Texas MD Anderson Cancer Center, or MD Anderson, including as Center Medical Director for MD Anderson's Clinical and Translational Research Center and as Associate Professor in its Department of Investigational Cancer Therapeutics where he focused his research efforts in oncogenic mutations and molecular aberrations.Dr. Janku's work has been recognized with multiple awards including the Emil Frei, III Award for Excellence in Translational Research, Sabin Family Fellow Award, Khalifa Scholar Award, Sidney Kimmel Scholar Award; and he authored or coauthored over 290 scientific articles in peer-reviewed journals. Dr. Janku received his M.D. and Ph.D. from Charles University in the Czech Republic.
- Philip Nickson
Philip Nickson，自2024年5月起担任Monte Rosa Therapeutics, Inc.首席业务和法务官。2022年3月至2024年4月，Nickson博士担任Monte Rosa Therapeutics, Inc.总法律顾问。从2021年3月到2022年3月，Nickson博士领导了Monte Rosa Therapeutics，Inc.的法律职能，担任Monte Rosa Therapeutics, Inc.法律运营主管。从2012年1月到2021年3月，Nickson博士在2020年10月被强生公司收购的摩蒙塔制药担任过越来越多的职务，最近担任知识产权副总裁和副总法律顾问。从2006年1月到2012年1月，Nickson博士曾在Fish and Richardson律师事务所担任多个职位，执业重点是支持中小型生物技术客户。在执业法律之前，尼克森博士在波士顿生物医学研究所完成了研究心肌细胞死亡的博士后研究项目。Nickson博士在萨福克大学获得法学博士学位，在曼彻斯特大学获得博士学位。
Philip Nickson,has served as Monte Rosa Therapeutics, Inc. Chief Business and Legal Officer since May 2024. From March 2022 to April 2024, Dr. Nickson served as Monte Rosa Therapeutics, Inc. General Counsel. From March 2021 to March 2022, Dr. Nickson led Monte Rosa Therapeutics, Inc. legal function serving as Monte Rosa Therapeutics, Inc. Head of Legal Operations. From January 2012 to March 2021, Dr. Nickson served in various roles of increasing responsibility at Momenta Pharmaceuticals, acquired by Johnson and Johnson in October 2020, including most recently as Vice President of Intellectual Property and Associate General Counsel. From January 2006 to January 2012, Dr. Nickson served in various positions at the law firm Fish and Richardson, with a practice focusing on supporting small to mid-size biotech clients. Prior to practicing law, Dr. Nickson completed a post-doctoral research program at the Boston Biomedical Research Institute researching cardiomyocyte cell death. Dr. Nickson received his J.D. from Suffolk University and his Ph.D. from University of Manchester.- Philip Nickson，自2024年5月起担任Monte Rosa Therapeutics, Inc.首席业务和法务官。2022年3月至2024年4月，Nickson博士担任Monte Rosa Therapeutics, Inc.总法律顾问。从2021年3月到2022年3月，Nickson博士领导了Monte Rosa Therapeutics，Inc.的法律职能，担任Monte Rosa Therapeutics, Inc.法律运营主管。从2012年1月到2021年3月，Nickson博士在2020年10月被强生公司收购的摩蒙塔制药担任过越来越多的职务，最近担任知识产权副总裁和副总法律顾问。从2006年1月到2012年1月，Nickson博士曾在Fish and Richardson律师事务所担任多个职位，执业重点是支持中小型生物技术客户。在执业法律之前，尼克森博士在波士顿生物医学研究所完成了研究心肌细胞死亡的博士后研究项目。Nickson博士在萨福克大学获得法学博士学位，在曼彻斯特大学获得博士学位。
- Philip Nickson,has served as Monte Rosa Therapeutics, Inc. Chief Business and Legal Officer since May 2024. From March 2022 to April 2024, Dr. Nickson served as Monte Rosa Therapeutics, Inc. General Counsel. From March 2021 to March 2022, Dr. Nickson led Monte Rosa Therapeutics, Inc. legal function serving as Monte Rosa Therapeutics, Inc. Head of Legal Operations. From January 2012 to March 2021, Dr. Nickson served in various roles of increasing responsibility at Momenta Pharmaceuticals, acquired by Johnson and Johnson in October 2020, including most recently as Vice President of Intellectual Property and Associate General Counsel. From January 2006 to January 2012, Dr. Nickson served in various positions at the law firm Fish and Richardson, with a practice focusing on supporting small to mid-size biotech clients. Prior to practicing law, Dr. Nickson completed a post-doctoral research program at the Boston Biomedical Research Institute researching cardiomyocyte cell death. Dr. Nickson received his J.D. from Suffolk University and his Ph.D. from University of Manchester.
- Jennifer Champoux
Jennifer Champoux，自2024年5月起担任Monte Rosa Therapeutics, Inc.首席运营官。Champoux女士于2021年3月加入Monte Rosa，担任运营高级副总裁。2023年3月至2024年5月，Champoux女士担任首席人事和运营官。在加入Monte Rosa之前，从2019年5月到2021年3月，Champoux女士担任H3 Biomedicine的运营执行总监，领导运营、通信和财务运营团队。在此之前，Champoux女士于2017年6月至2019年5月担任H3 Biomedicine的运营总监。从2006年2月到2017年5月，Champoux女士之前曾在诺华生物医学研究所工作，并担任过各种职责日益增加的角色，最终领导了剑桥探索化学小组的运营工作。Champoux女士的职业生涯始于多个药物开发职能，包括在默沙东和Array BioPharma的过程化学、项目管理和临床运营。Champoux女士拥有佛蒙特大学化学学士学位和印第安纳大学有机化学硕士学位。
Jennifer Champoux,has served as Monte Rosa Therapeutics, Inc. Chief Operating Officer since May 2024. Ms. Champoux joined Monte Rosa on March 2021 as Senior Vice President of Operations. From March 2023 to May 2024, Ms. Champoux served as Chief People and Operations Officer. Prior to joining Monte Rosa, from May 2019 to March 2021, Ms. Champoux was Executive Director of Operations at H3 Biomedicine where she led the operations, communications, and finance operations teams. Prior to that, Ms. Champoux was a Director, Operations at H3 Biomedicine from June 2017 to May 2019. From February 2006 to May 2017, Ms. Champoux previously worked at Novartis Institutes for Biomedical Research and served in various roles of increasing responsibility, ultimately leading operations for the Discovery Chemistry group in Cambridge. Ms. Champoux started her career in several pharmaceutical development functions, including process chemistry, program management, and clinical operations at Merck and Array BioPharma. Ms. Champoux holds a B.S. in chemistry from University of Vermont and a M.S in organic chemistry from Indiana University.- Jennifer Champoux，自2024年5月起担任Monte Rosa Therapeutics, Inc.首席运营官。Champoux女士于2021年3月加入Monte Rosa，担任运营高级副总裁。2023年3月至2024年5月，Champoux女士担任首席人事和运营官。在加入Monte Rosa之前，从2019年5月到2021年3月，Champoux女士担任H3 Biomedicine的运营执行总监，领导运营、通信和财务运营团队。在此之前，Champoux女士于2017年6月至2019年5月担任H3 Biomedicine的运营总监。从2006年2月到2017年5月，Champoux女士之前曾在诺华生物医学研究所工作，并担任过各种职责日益增加的角色，最终领导了剑桥探索化学小组的运营工作。Champoux女士的职业生涯始于多个药物开发职能，包括在默沙东和Array BioPharma的过程化学、项目管理和临床运营。Champoux女士拥有佛蒙特大学化学学士学位和印第安纳大学有机化学硕士学位。
- Jennifer Champoux,has served as Monte Rosa Therapeutics, Inc. Chief Operating Officer since May 2024. Ms. Champoux joined Monte Rosa on March 2021 as Senior Vice President of Operations. From March 2023 to May 2024, Ms. Champoux served as Chief People and Operations Officer. Prior to joining Monte Rosa, from May 2019 to March 2021, Ms. Champoux was Executive Director of Operations at H3 Biomedicine where she led the operations, communications, and finance operations teams. Prior to that, Ms. Champoux was a Director, Operations at H3 Biomedicine from June 2017 to May 2019. From February 2006 to May 2017, Ms. Champoux previously worked at Novartis Institutes for Biomedical Research and served in various roles of increasing responsibility, ultimately leading operations for the Discovery Chemistry group in Cambridge. Ms. Champoux started her career in several pharmaceutical development functions, including process chemistry, program management, and clinical operations at Merck and Array BioPharma. Ms. Champoux holds a B.S. in chemistry from University of Vermont and a M.S in organic chemistry from Indiana University.
- Andrew Schiff
Andrew Schiff，自2020年9月起担任Monte Rosa Therapeutics，Inc.董事会成员，自2023年6月起担任Monte Rosa Therapeutics，Inc.董事长。Schiff博士担任Aisling Capital的管理合伙人，Aisling Capital是一家风险投资公司，他自1999年以来一直隶属于该公司。在加入Aisling Capital之前，Schiff博士在纽约长老会医院从事内科工作，目前他在那里保持着医学临床助理教授的职位。Schiff博士自2017年起担任制药公司Aclaris Therapeutics, Inc.的董事会成员。Schiff博士获得了康奈尔大学医学院的医学博士学位、哥伦比亚大学商学院的工商管理硕士学位，以及布朗大学的神经科学荣誉学士学位。
Andrew Schiff,has been a member of Monte Rosa Therapeutics, Inc. board of directors since September 2020 and as Monte Rosa Therapeutics, Inc. chairman since June 2023. Dr. Schiff serves as a Managing Partner of Aisling Capital, a venture capital firm, that he has been affiliated with since 1999. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at the New York Presbyterian Hospital, where he currently maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff serves as a member of the board of directors of Aclaris Therapeutics, Inc., a pharmaceutical company, since 2017. Dr. Schiff received an M.D. from Cornell University Medical College, an M.B.A. from Columbia Business School, and a B.S. in neuroscience with honors from Brown University.- Andrew Schiff，自2020年9月起担任Monte Rosa Therapeutics，Inc.董事会成员，自2023年6月起担任Monte Rosa Therapeutics，Inc.董事长。Schiff博士担任Aisling Capital的管理合伙人，Aisling Capital是一家风险投资公司，他自1999年以来一直隶属于该公司。在加入Aisling Capital之前，Schiff博士在纽约长老会医院从事内科工作，目前他在那里保持着医学临床助理教授的职位。Schiff博士自2017年起担任制药公司Aclaris Therapeutics, Inc.的董事会成员。Schiff博士获得了康奈尔大学医学院的医学博士学位、哥伦比亚大学商学院的工商管理硕士学位，以及布朗大学的神经科学荣誉学士学位。
- Andrew Schiff,has been a member of Monte Rosa Therapeutics, Inc. board of directors since September 2020 and as Monte Rosa Therapeutics, Inc. chairman since June 2023. Dr. Schiff serves as a Managing Partner of Aisling Capital, a venture capital firm, that he has been affiliated with since 1999. Prior to joining Aisling Capital, Dr. Schiff practiced internal medicine at the New York Presbyterian Hospital, where he currently maintains his position as a Clinical Assistant Professor of Medicine. Dr. Schiff serves as a member of the board of directors of Aclaris Therapeutics, Inc., a pharmaceutical company, since 2017. Dr. Schiff received an M.D. from Cornell University Medical College, an M.B.A. from Columbia Business School, and a B.S. in neuroscience with honors from Brown University.